Institut Curie

Paris, Île-de-France Region 75248

4 studies enrolling now · 7 studies all time

What they study most

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, HER-2 Positive Breast Cancer, KRAS G12C-mutated Solid Tumors, Lung Cancer, KRAS, NRAS, HRAS-mutated NSCLC, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, Metastatic Neoplasm, Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, Prostate Cancer, RAS G12D-mutated NSCLC

Studies at this site

• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma — Recruiting now
• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC — Recruiting now
• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. — Recruiting now
• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
• Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer — Completed
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer — Completed